Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Ballentine Partners LLC

Ballentine Partners LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,571 shares of the medical equipment provider’s stock after purchasing an additional 716 shares during the quarter. Ballentine Partners LLC’s holdings in Zimmer Biomet were worth $483,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC boosted its stake in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $31,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $35,000. Finally, Quarry LP purchased a new position in Zimmer Biomet in the 2nd quarter worth approximately $53,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $110.93 on Friday. The firm has a 50 day moving average of $107.85 and a two-hundred day moving average of $108.07. The stock has a market capitalization of $22.08 billion, a PE ratio of 21.09, a P/E/G ratio of 1.89 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 52 week low of $100.67 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period last year, the business posted $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent research reports. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. BTIG Research cut their target price on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Evercore ISI lowered their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Barclays cut their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.